Lexicon Pharmaceuticals, Inc. (LXRX) Financial Statements (2024 and earlier)

Company Profile

Business Address 2445 TECHNOLOGY FOREST BLVD.
THE WOODLANDS, TX 77381
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments138,35786,743152,275271,659160,052310,788
Cash and cash equivalents46,34564,065126,26336,11280,38661,661
Short-term investments92,01222,67826,012235,54779,666249,127
Receivables281439556,5325,9244,825
Inventory, net of allowances, customer advances and progress billings   4,2434,6801,948
Inventory   4,2434,6801,948
Other current assets2,4812,1645,0495,3202,6684,434
Total current assets:140,86688,921157,719337,754173,324321,995
Noncurrent Assets
Operating lease, right-of-use asset    
Property, plant and equipment2,0711,17629514,04715,86517,687
Intangible assets, net (including goodwill)44,54344,54344,54364,25994,66296,428
Goodwill44,54344,54344,54344,54344,54344,543
Intangible assets, net (excluding goodwill)    19,71650,11951,885
Other noncurrent assets6,8192,2691,2311,655285429
Total noncurrent assets:53,43347,98846,06979,961110,812114,544
TOTAL ASSETS:194,299136,909203,788417,715284,136436,539
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities23,17222,12435,16054,32932,24169,934
Accounts payable10,3959,1525,46912,17817,75957,652
Accrued liabilities12,77712,97229,69142,15114,48212,282
Debt   11,64611,0121,11514,094
Deferred revenue and credits40,099
Other undisclosed current liabilities     3,395 
Total current liabilities:23,17222,12446,80665,34136,751124,127
Noncurrent Liabilities
Long-term debt and lease obligation, including:5,424  1,102243,887231,576
Long-term debt, excluding current maturities   234,171243,887231,576
Other undisclosed long-term debt and lease obligation 5,424  (233,069)  
Liabilities, other than long-term debt5,4241,1906111,1026,25228,734
Deferred revenue and credits22,428
Deferred tax liabilities, net6,0146,014
Other liabilities 5,4241,1906111,102238292
Operating lease, liability    
Other undisclosed noncurrent liabilities 43,155  233,06923,651 
Total noncurrent liabilities:54,0031,190611235,273273,790260,310
Total liabilities:77,17523,31447,417300,614310,541384,437
Equity
Equity, attributable to parent117,124113,595156,371117,101(26,405)52,102
Common stock189150142106106106
Treasury stock, value(2,061)(7,518)(4,843)(3,817)(2,876)(1,904)
Additional paid in capital1,709,1441,608,7491,561,0961,462,1721,447,9541,435,526
Accumulated other comprehensive income (loss)(428)(10)(6)84(12)(222)
Accumulated deficit(1,589,720)(1,487,776)(1,400,018)(1,341,444)(1,471,577)(1,381,404)
Total equity:117,124113,595156,371117,101(26,405)52,102
TOTAL LIABILITIES AND EQUITY:194,299136,909203,788417,715284,136436,539

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues13929823,995322,07363,20990,335
Revenue, net90,335
Cost of revenue  (1,929)(3,231)(2,491)(1,899)
Cost of goods and services sold  (1,929)(3,231)(2,491)(1,899)
Gross profit:13929822,066318,84260,71888,436
Operating expenses(100,899)(87,388)(204,380)(180,628)(166,488)(227,016)
Other undisclosed operating income (loss)  134,5143,2312,4911,899
Operating income (loss):(100,760)(87,090)(47,800)141,445(103,279)(136,681)
Nonoperating income
(Other Nonoperating income)
1,5961342,7673,3503,5081,954
Interest and debt expense(2,780)(802)(13,541)(20,676)(20,777)(6,984)
Income (loss) from continuing operations before income taxes:(101,944)(87,758)(58,574)124,119(120,548)(141,711)
Income tax benefit   2695,569 12,661
Income (loss) from continuing operations:(101,944)(87,758)(58,305)129,688(120,548)(129,050)
Income (loss) before gain (loss) on sale of properties:(87,758)(70,505)129,688(120,548)(129,050)
Loss from discontinued operations   (12,200)   
Other undisclosed net income   11,931445  
Net income (loss) available to common stockholders, basic:(101,944)(87,758)(58,574)130,133(120,548)(129,050)
Dilutive securities, effect on basic earnings per share  (87,758)(58,574)135,200  
Net income (loss) available to common stockholders, diluted:(101,944)(175,516)(117,148)265,333(120,548)(129,050)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net income (loss):(101,944)(87,758)(58,574)130,133(120,548)(129,050)
Comprehensive income (loss):(101,944)(87,758)(58,574)130,133(120,548)(129,050)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(418)(4)(90)96210(27)
Comprehensive income (loss), net of tax, attributable to parent:(102,362)(87,762)(58,664)130,229(120,338)(129,077)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: